FRIDAY, OCTOBER 11

8:30 – 9:00 am  OPENING CEREMONY

9:00 – 10:00 am  ORAL COMMUNICATIONS

OC1: Why do we need an Asian brain template in clinical trials of Alzheimer's disease? a comparative study of brain structures between Asian vs. Caucasian brains
Hyun Kook LIM (1), Dong Woo KANG (2), Sheng-Min WANG (3), Sung-Jin SON (4) - (1)Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, South Korea. (2)Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea (3)Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea – Seoul, South Korea, (4)NEUROPHET, Inc., Seoul, South Korea

OC2: The Phase 2 study of BAN2401 in early Alzheimer’s disease demonstrated both a dose-dependent reduction in brain amyloid plaques and slowing progression of clinical symptoms.
Keiichiro TOTSUKA - Eisai Co., Ltd., Japan

OC3: Continued large amyloid PET reductions at 36 months in the gantenerumab open-label extension studies
Gregory KLEIN (1), Paul DELMAR (2), Geoffrey A. KERCHNER (1), Carsten HOFMANN (1), Danielle ABI-SAAB (2), Smiljana RISTIC (2), Sunita REHAL (3), Nicola VOYLE (3), Monika BAUDLER (2), Paulo FONTAL (1), Rachelle DOODY (2) - (1)Roche Pharma Research and Early Development, Basel, Switzerland, (2)Roche/Genentech Product Development, Neuroscience, Basel, Switzerland (3)Roche Products Ltd, Welwyn Garden City, United Kingdom, (4)Genentech Inc., South San Francisco, USA

OC4: Sodium oligomannate therapeutically harnesses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression
Meiyu Geng1, Xinyi Wang2, Guangqiang Sun2, Teng Feng2, Jing Zhang2, Xun Huang1, Tao Wang3 and Zuoquan Xie1
1 State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
2 Shanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China.
3 Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine; Alzheimer’s Disease and Related Disorders Center, Shanghai Jiao Tong University, Shanghai, China

10:00 – 10:30 am  Coffee break and poster session

10:30 – 11:00 am  KEYNOTE 1: Chinese Medicine Point of View for Diagnosis and Treatment of AD
Piu Chan, MD, PhD - Professor and Director, Beijing Institute of Geriatrics, Department of Neurology, Neurobiology and Geriatrics, Xuanwu Hospital of Capital Medical University, National GCP Clinical Trial Center on Neurodegenerative Diseases, Beijing, China

11:00 – noon  SYMPOSIUM 1: BIOMARKER, AI IMAGING AND CLINICAL COHORT DEVELOPMENT IN CHINA

Presentation 1: China national clinical research center Alzheimer disease and Neurodegenerative Disorder Research (CANDOR study)
Jiong Shi, MD PhD FAAN, Department of Neurology
Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Presentation 2: Biofluid biomarkers in clinical phenotypes in Chinese patients
Yong Shen, MD, PhD

Presentation 3: How to assess cognitive impairment using MRI
### FRIDAY, OCTOBER 11

#### 12:00 – 1:00 pm
**Lunch**

#### 1:00 – 1:30 pm
**CONFERENCE 1:** What we have learned from past drug trials in AD, lessons for the future  
**Bruno Vellas, MD, PhD – Chair of the Gerontopole & Department of Geriatric Internal Medicine at the Toulouse University Hospital, Toulouse, France**

#### 1:30 – 2:30 pm
**ORAL COMMUNICATIONS**

<table>
<thead>
<tr>
<th>OC5</th>
<th>Plasma biomarkers promisingly differentiate Alzheimer's disease, Parkinson's disease and frontotemporal dementia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Huei-Ling LIU (1), Shieh-Yueh YANG (1), Ming-Jang CHIU (3), Chin-Hsien LIN (3), Wei-Che LIN (4), Fu-Chi YANG (5), Pai-Yi CHIU (6), W.P. CHEN (2) - (1) MagQu Co., Ltd., Taiwan, (2) MagQu LLC, USA, (3) National Taiwan University Hospital, Taiwan, (4) Kaohsiung Chang Gung Memorial Hospital, Taiwan, (5) Tri-Service General Hospital, Taiwan, (6) Show Chwan Memorial Hospital, Taiwan.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OC6</th>
<th>Inhibition of endocytic pathway of BACE1 as a therapeutic strategy for Alzheimer disease treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beka SOLOMON - Tel Aviv university, Israeil</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OC7</th>
<th>Correlation between amyloid reduction and clinical outcomes: exploratory analyses from the gantenerumab Scarlet RoAD and Marguerite RoAD open-label extension studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory KLEIN (1), Paul DELMAR (2), Geoffrey A. KERCHNER (2), Guoqiao WANG (3), Randall BATEMAN (3), Sunita REHAL (4), Nicola VOYLE (4), Mirjana ANDJELKOVIC (2), Danielle ABI-SAAB (2), Szofia BULLAIN (2), Smiljana RISTIC (2), Monika BAUDLER (2), Paolo FONTOURA (2), Rachelle DOODY (2) - (1) Roche/Genentech Product Development, Neuroscience, Basel, Switzerland, (2) Roche Pharma Research and Early Development, Basel, Switzerland, (3) Washington University, School of Medicine, USA, (4) Roche Products Development Ltd, Welwyn Garden City, UK, (5) Genentech Inc., South San Francisco, USA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OC8</th>
<th>Longitudinal trajectories of Alzheimer’s ATN biomarkers in nondemented elderly adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jin-Tai YU (1), Meng-Shan TAN (2), Xi JI (3), Jie-Qiong LI (2), Qiang DONG (1), Chuan-Tao ZOU (1), Lan TAN (2), John SUCKLING (4) - (1) Huashan Hospital, Shanghai Medical College, Fudan University, China, (2) Qingdao Municipal Hospital, Qingdao University, China, (3) Dalian Medical University, China, (4) University of Cambridge, UK</td>
<td></td>
</tr>
</tbody>
</table>

#### 2:30 – 3:00 pm
**ROUND TABLE: CHINA FDA**

#### 3:00 – 3:30 pm
**Coffee break and poster session**

**SYMPOSIUM 2: HOW TO DESIGN A CLINICAL TRIAL PROTOCOL IN AD**

- **Presentation 1:** Primary outcomes  
- **Presentation 2:** Secondary outcomes  
- **Presentation 3:** Use of biomarkers (CSF, blood, imaging)

#### 4:30 – 5:30 pm
**LATE BREAKING ORAL COMMUNICATIONS**
8:30 – 9:00 am  
**LATE BREAKING ORAL COMMUNICATIONS**

- **LB5**
- **LB6**

9:00 – 10:00 am  
**ORAL COMMUNICATIONS**

- **OC9:** Collaborative Global-Local Network for Classification of Patients with Alzheimer’s Diseases and Cognitively Unimpaired Individuals: A Neurodegeneration Assessment Tool for Patient inclusion in AD trial  
  Kewei CHEN (1), Wuyang CHEN (1), Ye YUAN (1), Eric REIMAN (2), Xiaofen LIU (1), Frank LEE (4), Yaojing CHEN (3), Zhanjun ZHANG (3), Zhangyang WANG (1)  
  (1)Shanghai Green Valley Pharmaceutical, China, (2)Banner Alzheimer's Institute, USA  
  (3)State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University, China, (4)Green Caddy LLC, USA

- **OC10:** Endothelial BACE1-mediated cleavage of occludin contributes to cerebral small vessel pathology and neuronal dysfunction  
  Feng GAO - University of Science and Technology of China, China

- **OC11:** Microtubule-associated protein 1B rescues memory decline in Alzheimer’s disease model mice  
  Fuyuki MITSUYAMA - Tenjyu Hospital, Japan

- **OC12:** Cerebrovascular Disease and Alzheimer's Disease  
  Yicheng ZHU Department of Neurology, Peking Union Medical College Hospital, Beijing, China

10:00 – 10:30 am  
**Coffee break and poster session**

10:30 – 11:00 am  
**KEYNOTE 2:** Chinese National Clinical Research Center for Dementia Platform  
Jiong Shi MD, PhD, FAAN - Professor, Department of Neurology, Barrow Neurological Institute, Phoenix, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 12:00 pm</td>
<td>SYMPOSIUM 2 (TO BE ANNOUNCED)</td>
</tr>
<tr>
<td>12:00 – 1:00 pm</td>
<td>Lunch and poster sessions</td>
</tr>
</tbody>
</table>
| 1:00 – 1:30 pm  | CONFERENCE 2: Past, Present and Future of Alzheimer Disease – Where we are now in 2019?  
Jacques Touchon, MD, PhD – University Hospital of Montpellier, Montpellier, France |
| 1:30 – 2:30 pm  | LATE BREAKING ORAL COMMUNICATIONS                                    |
| 2:30 – 3:00 pm  | KEYNOTE 3: AD clinical trials and related activities in Japan         |
Takeshi Iwatsubo, MD, PhD – Professor of Neuropathology at the School of Medicine, University of Tokyo, Tokyo, Japan |
| 3:00 – 3:30 pm  | Coffee break and poster session                                       |
| 3:30 – 4:30 pm  | LATE BREAKING ORAL COMMUNICATIONS                                    |
| 4:30 – 5:00 pm  | CLOSING CEREMONY                                                      |